Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

EC in Japan

This article was originally published in The Tan Sheet

Executive Summary

Tokyo, Japan-based firm Sosei Group announces Nov. 17 the commencement of a Phase I clinical trial for the emergency contraceptive pill SOH-075 (NorLevo). The clinical trial is a randomized, double-blind, placebo-controlled study on a total of 33 Japanese adult female volunteers in three cohorts at a single study center. This will be the first emergency contraceptive pill introduced in Japan, the company says. The firm says it acquired the exclusive distribution rights to the product in Japan from Laboratoire HRA Pharma. In the U.S., Barr's emergency contraceptive pill Plan B became available for age-restricted sale behind pharmacy counters this month (1"The Tan Sheet" Nov. 13, 2006, p. 8)...

You may also be interested in...



Dual Package Plan B Hits Shelves Mid-November With Three-Year Exclusivity

The first product to be approved in a single package for both Rx and OTC sale - Barr Pharmaceuticals' emergency contraceptive Plan B - will be available behind pharmacy counters by mid-November, according to the firm

Ready, Set, Guidance: FDA Releases Final Details Ahead Of ASCA Pilot Launch

A trio of newly finalized guidance documents from the US agency dated 25 September explain how the Accreditation Scheme for Conformity Assessment pilot will work, and what biocompatibility and safety standards will apply.

With Preservative-Free Alaway Eye Drops, Bausch Expands OTC Portfolio Of Planned Spin-Off

Approval of Alaway Preservative Free (ketotifen fumarate, 0.035) comes 15 months after FDA submitted a complete response letter to Bausch and the active ingredient developer, Eton Pharmaceuticals. 

Topics

UsernamePublicRestriction

Register

SC081785

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel